title: Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study.
abstract: OBJECTIVE
  To assess the safety and feasibility of acute transport followed by rescue percutaneous transluminal coronary angioplasty (PTCA) or primary PTCA in patients with acute myocardial infarction initially admitted to a hospital without PTCA facilities.
  
  
  METHODS
  In a multicentre randomised open trial, three regimens of treatment of acute large myocardial infarction were compared for patients admitted to hospitals without angioplasty facilities: thrombolytic treatment with alteplase (75 patients), alteplase followed by transfer to the PTCA centre and (if indicated) rescue PTCA (74 patients), or transfer for primary PTCA (75 patients).
  
  
  RESULTS
  Between 1995 and 1997 224 patients were included. Baseline characteristics were distributed evenly. Transport to the PTCA centre was without severe complications in all patients. Mean (SD) delay from onset of symptoms to randomisation was 130 (75) minutes and from randomisation to angiography 90 (25) minutes. Death or recurrent infarction within 42 days occurred in 12 patients in the thrombolysis group, in 10 patients in the rescue PTCA group, and in six patients in the primary PTCA group. These differences were not significant.
  
  
  CONCLUSIONS
  Acute transfer for rescue PTCA or primary PTCA in patients with extensive myocardial infarction is feasible and safe. Efficacy of rescue PTCA or primary PTCA in this setting will have to be tested in larger series before this approach can be implemented as "routine treatment" for patients with extensive myocardial infarction.
authors.affiliation: University Hospital Maastricht, Department of Cardiology, PO Box 5800, 6202 AZ, Maastricht, Netherlands. F.Vermeer@cardio.azm.nl
authors.forename: F
authors.initials: F
authors.lastname: Vermeer
authors.forename: A J
authors.initials: AJ
authors.lastname: Oude Ophuis
authors.forename: E J
authors.initials: EJ
authors.lastname: vd Berg
authors.forename: L G
authors.initials: LG
authors.lastname: Brunninkhuis
authors.forename: C J
authors.initials: CJ
authors.lastname: Werter
authors.forename: A G
authors.initials: AG
authors.lastname: Boehmer
authors.forename: A H
authors.initials: AH
authors.lastname: Lousberg
authors.forename: W R
authors.initials: WR
authors.lastname: Dassen
authors.forename: F W
authors.initials: FW
authors.lastname: Bär
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000706:statistics & numerical data*; D004638:Emergency Treatment; D005240:Feasibility Studies; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000628:therapy*; D010360:Patient Transfer; D010865:Pilot Projects; D011446:Prospective Studies; D015912:Thrombolytic Therapy / Q000706:statistics & numerical data*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator